Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell-Mediated Antitumor Responses

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 10, 2008, Pages 1088-1099

  Hallett, William H D ^a   Ames, Erik ^a   Álvarez, Maite ^a   Barao, Isabel ^a   Taylor, Patricia A ^b   Blazar, Bruce R ^b   Murphy, William J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Natural killer cells; Regulatory T cells

Indexed keywords

BASILIXIMAB; CD8 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; IMMUNOREGULATION; IN VIVO STUDY; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MONOTHERAPY; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOTOXICITY, IMMUNOLOGIC; IMMUNOTHERAPY; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 51649084785     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.08.001     Document Type: Article

References (46)

1. Cudkowicz G., and Bennett M. Peculiar immunobiology of bone marrow allografts, I: graft rejection by irradiated responder mice. J Exp Med 134 (1971) 83-102
2. Herberman R.B., and Ortaldo J.R. Natural killer cells: their roles in defenses against disease. Science 214 (1981) 24-30
3. Trinchieri G. 1989. Biology of natural killer cells. Adv Immunol 47 (1989) 187-376
4. Dredge K., Marriott J.B., Todryk S.M., et al. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 51 (2002) 521-531
5. Trinchieri G., Wysocka M., D'Andrea A., et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Progr Growth Factor Res 4 (1992) 355-368
6. Gerosa F., Gobbi A., Zorzi P., et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 174 (2005) 727-734
7. Geldhof A.B., Van Ginderachter J.A., Liu Y., et al. Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood 100 (2002) 4049-4058
8. Kelly J.M., Darcy P.K., Markby J.L., et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3 (2002) 83-90
9. Hallett W.H., and Murphy W.J. Positive and negative regulation of natural killer cells: therapeutic implications. Semin Cancer Biol 16 (2006) 367-382
10. *. Annu Rev Immunol 18 (2000) 423-449
11. + regulatory T cells induced by chronic retroviral infection. Proc Natl Acad Sci U S A 98 (2001) 9226-9230
12. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 112 (2003) 1688-1696
13. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202 (2005) 1075-1085
14. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176 (2006) 1582-1587
15. + regulatory T cells. Proc Natl Acad Sci U S A 103 14 (2006) 5460-5465
16. Mule J.J., Shu S., Schwarz S.L., et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225 (1984) 1487-1489
17. Rosenberg S.A., Mule J.J., Spiess P.J., et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161 (1985) 1169-1188
18. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28 (2005) 120-128
19. Sayers T.J., Brooks A.D., Seki N., et al. T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas. J Leukocyte Biol 68 (2000) 81-86
20. McDermott D.F., and Atkins M.B. Application of IL-2 and other cytokines in renal cancer. Exp Opin Biol Ther 4 (2004) 455-468
21. Andersen M.H., Gehl J., Reker S., et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 13 (2003) 449-459
22. Rosmaraki E.E., Douagi I., Roth C., et al. Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol 31 (2001) 1900-1909
23. Hallett W.H., Ames E., Motarjemi H., et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 180 (2008) 163-170
24. Tamang D.L., Redelman D., Alves B.N., et al. Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. Cytokine 36 (2006) 148-159
25. Assarsson E., Kambayashi T., Sandberg J.K., et al. CD8+ T cells rapidly acquire NK1.1 and NK cell-associated molecules upon stimulation in vitro and in vivo. J Immunol 165 (2000) 3673-3679
26. Fehniger T.A., Cai S.F., Cao X., et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26 (2007) 798-811
27. Abdool K., Cretney E., Brooks A.D., et al. NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function. J Immunol 177 (2006) 2575-2583
28. + regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 98 (2007) 416-423
29. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 33 (2006) S11-S16
30. Barnett B., Kryczek I., Cheng P., et al. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54 (2005) 369-377
31. Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
32. + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120 (2007) 2723-2733
33. - subpopulations. J Immunol 165 (2000) 3105-3110
34. Apostolou I., Sarukhan A., Klein L., et al. Origin of regulatory T cells with known specificity for antigen. Nat Immunol 3 (2002) 756-763
35. + T regulatory cells. J Immunol 176 (2006) 3301-3305
36. + T regulatory cells," by Kohm AP, McMahon LS, Podojil JR, et al. J Immunol 177 (2006) 2036-2037 author reply, 2037-2038
37. + T regulatory cells," by Kohm AP, McMahon LS, Podojil JR, et al. J Immunol. 177:2036; author reply, 2037-2038.
38. + natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med 172 (1990) 1101-1114
39. Soiffer R.J., Murray C., Cochran K., et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79 (1992) 517-526
40. + CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107 (2006) 2409-2414
41. Fontenot J.D., Rasmussen J.P., Gavin M.A., et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6 (2005) 1142-1151
42. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212 (2006) 8-27
43. Taniguchi T., and Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 73 (1993) 5-8
44. Voss S.D., Sondel P.M., and Robb R.J. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R. J Exp Med 176 (1992) 531-541
45. Shah M.H., Freud A.G., Benson Jr. D.M., et al. A phase I study of ultra- low-dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 12 (2006) 3993-3996
46. + regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol 19 (2007) 785-799